期刊
JOURNAL OF CLINICAL IMMUNOLOGY
卷 41, 期 7, 页码 1582-1596出版社
SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s10875-021-01073-9
关键词
EBV; Hemophagocytic lymphohistiocytosis; HLH; Epstein-Barr virus; T cells
类别
资金
- Raymond F. Schinazi International Exchange Program (SIEP), Emory University School of Medicine, Atlanta, USA
- NHLBI [1K08HL141635-01A1]
- Mills Foundation
- Henagan Foundation
- [K12HD072245]
- [U54AI082973]
T cell-EBV-HLH is found in the USA, especially among non-Asian populations such as Hispanics. Most patients do not have primary HLH gene defects, but disease severity and treatment response are correlated. The majority of patients respond well to immunosuppressive therapy.
Purpose T cell-Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (T cell-EBV-HLH) is prevalent in East Asia and has poor prognosis. Understanding of this disease is limited, and literature regarding prevalence in North America is scarce. Herein, we summarize our experience. Methods A retrospective analysis of T cell-EBV-HLH patients admitted to Children's Healthcare of Atlanta (GA, USA) from 2010 to 2020 was conducted. Additional immune studies were completed in a subset of patients. Results We report 15 patients (10 months-19 years of age) diagnosed with T cell-EBV-HLH. Nine patients were Hispanic, and the majority did not have primary HLH (p-HLH) gene defects. Soluble interleukin-2 receptor levels in T cell-EBV-HLH were significantly higher than other forms of secondary-HLH but comparable to p-HLH, and it correlated with disease severity at presentation. Natural killer cell function was decreased in most patients despite a negative workup for p-HLH. Depending on disease severity, initial therapy included dexamethasone or dexamethasone and etoposide. Refractory patients were managed with blended regimens that included one or more of the following therapies: combination chemotherapy, alemtuzumab, emapalumab, and nivolumab. Rituximab did not appreciably decrease EBV viremia in most patients. Non-critically ill patients responded well to immunosuppressive therapy and are long-term survivors without undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Alemtuzumab resulted in inflammation flare in two of the three patients. Three patients underwent allogeneic HSCT, with disease relapse noted in one. At a median follow-up of 3 years, 10 of the 15 patients are alive. Conclusion T cell-EBV-HLH occurs in the USA among the non-Asian populations, especially in those who are Hispanic.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据